IDEAYA Biosciences, Inc. $IDYA Position Raised by Fiera Capital Corp

Fiera Capital Corp boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 32.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,437,262 shares of the company’s stock after buying an additional 599,295 shares during the quarter. Fiera Capital Corp owned 2.78% of IDEAYA Biosciences worth $84,256,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. BIT Capital GmbH grew its position in IDEAYA Biosciences by 459.8% in the fourth quarter. BIT Capital GmbH now owns 16,900 shares of the company’s stock worth $584,000 after buying an additional 13,881 shares during the last quarter. Parallel Advisors LLC grew its position in IDEAYA Biosciences by 23.4% in the fourth quarter. Parallel Advisors LLC now owns 3,847 shares of the company’s stock worth $133,000 after buying an additional 730 shares during the last quarter. TD Asset Management Inc grew its position in IDEAYA Biosciences by 74.1% in the fourth quarter. TD Asset Management Inc now owns 46,040 shares of the company’s stock worth $1,592,000 after buying an additional 19,600 shares during the last quarter. Lido Advisors LLC acquired a new position in IDEAYA Biosciences in the fourth quarter worth approximately $1,913,000. Finally, Goldman Sachs Group Inc. grew its position in IDEAYA Biosciences by 43.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,770,866 shares of the company’s stock worth $61,219,000 after buying an additional 537,753 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

NASDAQ IDYA opened at $28.29 on Monday. IDEAYA Biosciences, Inc. has a twelve month low of $20.50 and a twelve month high of $39.28. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of -17.68 and a beta of -0.04. The firm’s 50 day moving average price is $30.19 and its two-hundred day moving average price is $32.64.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The business had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter last year, the firm posted ($0.82) EPS. The business’s quarterly revenue was down 39.4% on a year-over-year basis. On average, research analysts forecast that IDEAYA Biosciences, Inc. will post -4.27 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Mizuho decreased their price target on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Tuesday, April 21st. Wedbush restated an “outperform” rating and issued a $58.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, June 2nd. Truist Financial set a $65.00 price objective on shares of IDEAYA Biosciences in a research report on Monday, April 13th. Finally, Citigroup reiterated a “market outperform” rating on shares of IDEAYA Biosciences in a research report on Tuesday, June 2nd. Fifteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and an average target price of $50.69.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.